Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer We evaluated 62 consecutive patients undergoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback